Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eicosapentaenoic acid + L-5-methyltetrahydrofolate
- Development stage
- Unknown
- Lead developer
- Fenix Health Science
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
eicosapentaenoic acid + L-5-methyltetrahydrofolate is a combination dietary supplement known under the brand name CreNeuroS. It combines eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, with L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate. EPA acts as a ligand for peroxisome proliferator-activated receptors (PPARs), particularly PPAR-alpha, which mediates triglyceride reduction and exerts anti-inflammatory effects. L-5-MTHF serves as a critical methyl donor in the one-carbon metabolism cycle, bypassing the MTHFR enzyme to support the conversion of homocysteine to methionine and the synthesis of monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine. The combination is primarily developed as a nutraceutical to support cardiovascular and neurological health, and has been evaluated in pharmacokinetic trials to assess the bioavailability of its components.
- Brand names
- CreNeuroSCreNeuroS CNS Fish Oil Plus Softgels
- Other names
- EPA + L-5-MTHFEPA + levomefolate calciumeicosapentaenoic acid + calcium L-5-methyltetrahydrofolate
02
Targets
MTR (Methionine synthase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on eicosapentaenoic acid + L-5-methyltetrahydrofolate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eicosapentaenoic acid + L-5-methyltetrahydrofolate.